Clinical Trials Logo

HER2-Positive Solid Tumors clinical trials

View clinical trials related to HER2-Positive Solid Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04660929 Active, not recruiting - Breast Cancer Clinical Trials

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

NCT ID: NCT04460456 Active, not recruiting - Clinical trials for HER2 Positive Solid Tumors

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Start date: July 27, 2020
Phase: Phase 1
Study type: Interventional

A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies

NCT ID: NCT04278144 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Start date: February 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

NCT ID: NCT04189211 Active, not recruiting - Clinical trials for HER2-Positive Solid Tumors

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

Start date: March 7, 2017
Phase: Phase 1
Study type: Interventional

An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients with HER2-Positive Solid Tumors (breast cancer or gastric cancer)。